[Skip to Content]

Claim CME

Infectious Diseases

Evaluation of Risk Factors for Postbooster Omicron COVID-19 Deaths in England

Educational Objective
To identify the key insights or developments described in this article

1 Credit CME

JAMA Network Open

Published Online: September 8, 2022

Research Letter

Article Information and Disclosures

Vahé Nafilyan, PhD¹;

Isobel L. Ward, PhD¹;

Chris Robertson, PhD^2,3;

Aziz Sheikh, MD⁴;

for the National Core Studies—Immunology Breakthrough Consortium

Author Affiliations

¹Health Analysis and Life Events Division, Office for National Statistics, Newport, United Kingdom
²Department of Mathematics and Statistics, University of Strathclyde, Glasgow, United Kingdom
³Public Health Scotland, Glasgow, United Kingdom
⁴Usher Institute, University of Edinburgh, Edinburgh, United Kingdom

National Core Studies—Immunology Breakthrough Consortiumfor the

Read article on JAMA Network

Read Article Claim CME

With the emergence of the Omicron variant, it has become critical to identify risk factors associated with COVID-19 death in individuals who have completed primary vaccination and received a messenger RNA (mRNA) booster dose. Existing evidence is based on people who have received 1 or 2 doses of a COVID-19 vaccine and were infected by the Alpha or Delta variant.¹^- 3 Understanding which groups are at increased risk of COVID-19 death after receiving a booster is crucial for the prioritization of further booster doses and access to COVID-19 therapeutics.

Claim CME

Sign in to take quiz and track your certificates

Buy This Activity

Article Information

Accepted for Publication: August 8, 2022.

Published: September 8, 2022. doi:10.1001/jamanetworkopen.2022.33446

Correction: This article was corrected on September 29, 2022, to fix a row label in the Table (Sickle cell and severe combined immunodeficiency syndrome). Severe combined immunodeficiency syndrome has been removed and the data are now presented correctly.

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Nafilyan V et al. JAMA Network Open.

Corresponding Author: Isobel L.Ward, PhD, Office for National Statistics, Government Buildings, Cardiff Road, Newport, NP10 8XG, United Kingdom (isobel.ward@ons.gov.uk).

Author Contributions: Drs Nafilyan and Ward had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Nafilyan and Ward contributed equally.

Concept and design: All authors.

Acquisition, analysis, or interpretation of data: Nafilyan, Ward, Roberston.

Drafting of the manuscript: Nafilyan, Ward.

Critical revision of the manuscript for important intellectual content: Ward, Roberston, Sheikh.

Statistical analysis: Nafilyan, Ward.

Obtained funding: Nafilyan, Sheikh.

Administrative, technical, or material support: Nafilyan, Ward, Sheikh.

Supervision: Nafilyan, Roberston.

Conflict of Interest Disclosures: Dr Roberston reported service as a member of UK and Scottish government advisory committees, including the Scientific Pandemic Influenza Group on Modeling, Scottish Government Scientific Advisory Committee, and Medicines and Healthcare products Regulatory Agency COVID vaccine benefit and risk expert working group. Dr Sheikh reported service in uncompensated advisory roles on COVID-19 to UK and Scottish Governments and AstraZeneca. No other disclosures were reported.

Funding/Support: This research was funded by the National Core Studies–Immunity and received additional support from National Core Studies–Data and Connectivity, Health Data Research UK, and the Medical Research Council.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Meeting Presentation: This work has been accepted for a Rapid Fire talk at the Royal Statistical Society International Conference; September 12-15, 2022; Aberdeen, Scotland.

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
1.00 credit toward the CME [and Self-Assessment requirements] of the American Board of Surgery’s Continuous Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.